The American Journal of Surgery
Volume 197, Issue 4 , Pages 466-472 , April 2009

Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma

  • Richard A. Smith, M.R.C.S.

      Affiliations

    • Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby St., Liverpool, L69 3GA, UK
    • Corresponding Author InformationCorresponding author. Tel.: +00-44-0151-7063898; fax: +00-44-0151-7065826
    • ,
  • Lorraine Bosonnet, P.G.Dip.

      Affiliations

    • Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby St., Liverpool, L69 3GA, UK
    • ,
  • Michael Raraty, F.R.C.S.

      Affiliations

    • Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby St., Liverpool, L69 3GA, UK
    • ,
  • Robert Sutton, F.R.C.S.

      Affiliations

    • Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby St., Liverpool, L69 3GA, UK
    • ,
  • John P. Neoptolemos, F.R.C.S.

      Affiliations

    • Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby St., Liverpool, L69 3GA, UK
    • ,
  • Fiona Campbell, F.R.C.Path.

      Affiliations

    • Department of Pathology, School of Cancer Studies, Royal Liverpool University Hospital, Liverpool, UK
    • ,
  • Paula Ghaneh, F.R.C.S.

      Affiliations

    • Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby St., Liverpool, L69 3GA, UK

Received 10 October 2007 ,Revised 6 December 2007

References 

  1. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91:1410–1427
  2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210
  3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277
  4. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758–768
  5. Bassi C, Stocken DD, Olah A, et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg. 2005;22:353–363
  6. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–1210
  7. Connor S, Bosonnet L, Ghaneh P, et al. Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. Br J Surg. 2004;91:1592–1599
  8. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141:610–618
  9. Sierzega M, Popiela T, Kulig J, et al. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas. 2006;33:240–245
  10. Berger AC, Watson JC, Ross EA, et al. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004;70:235–240
  11. Kim J, Reber HA, Dry SM, et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut. 2006;55:1598–1605
  12. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erb-B3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89:469–474
  13. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–184
  14. Yamaguchi K, Noshiro H, Shimizu S, et al. Long-term and short-term survivors after pancreatectomy for pancreatic cancer. Int Surg. 2000;85:71–76
  15. Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32:22–28
  16. Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology. 2001;48:1493–1498
  17. Suzuki K, Aiura K, Kitagou M, et al. Platelet counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology. 2004;51:847–853
  18. Brown KM, Domin C, Aranha GV, et al. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg. 2005;189:278–282
  19. Shimada H, Oohira G, Okazumi S, et al. Thrombocytosis associated with poor prognosis in patients with oesophageal carcinoma. J Am Coll Surg. 2004;198:737–741
  20. Monreal M, Fernandez-Llamazares J, Pinol M, et al. Platelet count and survival in colorectal cancer—a preliminary study. Thromb Haemost. 1998;79:916–918
  21. Campbell F, Bennett M, Foulis AJ. Minimum dataset for histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma. Royal Coll Pathol. 2002;Available: http://www.rcpath.org. Accessed October 9, 2007.
  22. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor escape. Cytokine Growth Factor Rev. 2007;18:171–182
  23. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 1999;155:537–547
  24. Bellone G, Smirne C, Angelo F, et al. Cytokine expression in human pancreatic carcinoma cells in surgical specimens: implications for survival. Cancer Immunol Immunother. 2006;55:684–698
  25. Romano F, Uggeri F, Crippa S, et al. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res. 2004;23:195–200
  26. Fukunaga A, Miyamoto M, Yasushi C, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:26–31
  27. von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7(Suppl):925s–932s
  28. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004;5:655–663
  29. Haas SL, Jesnowski R, Steiner M, et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol. 2006;12:4843–4849
  30. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue Factor expression, angiogenesis and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–2875
  31. Nitori N, Ino Y, Nakanishi T, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531–2539
  32. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22:913–922
  33. Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003;26:135–140
  34. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30:95–108
  35. Suzuki K, Aiura K, Ueda M, et al. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas. 2004;29:132–140
  36. Jamieson NB, Glen P, McMillan DC, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer. 2005;92:21–23
  37. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92:651–654
  38. Crumley ABC, McMillan DC, McKernan M, et al. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94:1568–1571
  39. Sultana A, Tudor-Smith C, Cunningham D, et al. Systematic review, including meta-analysis, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96:1183–1190
  40. Sewnath ME, Karsten TM, Prins MH, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 2002;236:17–27
  41. Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–835
  42. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA19-9 and CEA in periampullary cancers. J Am Coll Surg. 1999;188:415–420

PII: S0002-9610(08)00344-9

doi: 10.1016/j.amjsurg.2007.12.057

The American Journal of Surgery
Volume 197, Issue 4 , Pages 466-472 , April 2009

Article Tools

* Image Usage & Resolution